Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.
about
Cardiotoxicity in childhood cancer survivors: strategies for prevention and managementSuicide ideation in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor StudyOrthotopic Heart Transplantation and Mechanical Circulatory Support in Cancer Survivors: Challenges and OutcomesCurrent Views on Anthracycline Cardiotoxicity in Childhood Cancer SurvivorsIs it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.Long-term consequences of hematopoietic stem cell transplantation: current state of the science.Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines.Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivorsCardiovascular disease in adult survivors of childhood cancer.Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Comparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experience.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study.Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsNational Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage aNT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivorsManaging chemotherapy-related cardiotoxicity in survivors of childhood cancers.Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohortRecommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.The prevention of cardiovascular disease in cancer survivors.Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at higStrategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.Reproductive outcomes for survivors of childhood cancer.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects.Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems databaseCardiotoxicity of childhood cancer treatment: update and current knowledge on long-term follow-up.ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs--threshold doses for tissue reactions in a radiation protection context.Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.Imaging of early modification in cardiomyopathy: the doxorubicin-induced model.Treatment-related cardiotoxicity in survivors of childhood cancer.
P2860
Q24628695-E2964346-619D-4C17-B5FB-182B3952DA9EQ24654190-30B34413-EB33-480C-B697-7157D36A59F7Q26785414-52F4728C-6E03-4E7F-8C8C-8B768996973AQ28083073-5B9C7D10-9C6C-4AEA-B208-21B2A4D15953Q30244600-328143CB-5F54-4F02-AF8C-69851181A483Q33341069-FFE3A68D-BFC1-41EA-8F39-45BBE756691CQ33705877-04173FAC-A036-4228-AE9C-AD98F3016763Q33739871-50D66B2A-7CF9-484C-B508-3FFDAF276981Q33948488-E7ED80E8-E7BF-40B6-8EA8-502CF566ACFEQ34042984-D7B0E7D9-EE64-4BAB-A230-3EDD4B3D19E4Q34563378-99494405-93A1-46EE-83EE-EEF5C1FF2778Q34572109-653519EB-BFC3-459D-9DAF-31CD3CA8944CQ34617599-F0D071FE-4F7D-441B-A8D2-6A151C612837Q34626238-5BDEE804-A9BE-4E9E-8121-39B69A0A1879Q34717844-832F8E6A-DD1D-4E78-8E70-D20C0709442DQ34822530-D687CF1B-C71D-4DC7-8C28-13F9D23F0E31Q35076156-8C6B684F-A004-4E85-AF0E-3AD6549C5EAEQ35327266-0A21C85B-D3E2-4F4C-9385-89AC4B0F44B9Q35549037-2C2BEC02-914B-43FB-A4F3-9D3808D9EB0AQ35557142-491DC73B-15E1-482E-B819-5A221A895138Q35562745-A161F4BF-40FA-4B94-B7A8-39D7E5538310Q35699184-1AAE2E68-FA6B-4EA3-AF80-2DDA26DDCC71Q35797623-31571A3B-3866-4867-A6B1-69CEAF150519Q36061056-3846CF03-28AD-4AA4-923B-E98F8ACD5F5CQ36156912-289D4B70-61DD-455E-BA72-BBC6258ACE4CQ36184665-525F9298-3994-42A1-9EEF-84274A9289DBQ36479962-06166937-97C6-4BA2-8BAF-25D1EAD40368Q36509306-2BF91668-F619-4ABE-AFA7-2CBE7D813125Q36568908-BD3D6062-9B1F-4BA0-B8AF-91F1A391FBFDQ36828128-1BECF34C-E160-4898-8FAE-4FF95E7904E2Q37167767-7892BEC3-D9E6-4068-8B85-512BE078112AQ37237505-D2BD76E4-70BC-4025-B018-A0B782F9BDD7Q37390119-7FCEA548-F741-4B91-972A-C22EA4666361Q37569911-F65E76CD-A7B2-4E3E-9C8A-D01F65839CF5Q38021523-5CD8D47D-5069-4151-8CC7-1E7FF811361CQ38038330-C37F0FEF-D5BC-4D06-8AB9-142FC4D96AEBQ38077713-2FCB571F-98AD-4FC8-B390-E8E2931891DAQ38109236-A1ECD3AB-11D1-413A-935D-288F789253D2Q38112616-57025FFE-C960-4A97-8F09-5A445B1BCE60Q38156036-EE00614C-077F-4ACA-B21F-1A9ED7126DB8
P2860
Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pathophysiology of anthracycli ...... for screening and prevention.
@ast
Pathophysiology of anthracycli ...... for screening and prevention.
@en
type
label
Pathophysiology of anthracycli ...... for screening and prevention.
@ast
Pathophysiology of anthracycli ...... for screening and prevention.
@en
prefLabel
Pathophysiology of anthracycli ...... for screening and prevention.
@ast
Pathophysiology of anthracycli ...... for screening and prevention.
@en
P356
P1476
Pathophysiology of anthracycli ...... for screening and prevention.
@en
P2093
M Jacob Adams
Steven E Lipshultz
P2860
P304
P356
10.1002/PBC.20352
P577
2005-06-01T00:00:00Z